Completed

STUCOpen-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

quetiapine

Drug
Who is being recruted

Mental Disorders+1

+ Marijuana Abuse

+ Substance-Related Disorders

From 18 to 65 Years
+15 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: August 2009
See protocol details

Summary

Principal SponsorNew York State Psychiatric Institute
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2009

Actual date on which the first participant was enrolled.

Conceptually, the pharmacodynamic and clinical actions of quetiapine suggest that it may be useful for cannabis dependence. By antagonizing dopamine, quetiapine may interfere with the reinforcing effects of cannabis, while serotonin type 2A, histamine type 1, and adrenergic receptor antagonism may reduce cannabis withdrawal symptoms, primarily by sedating and anxiolytic effects. The proposed research project is an open-label pilot study to evaluate the tolerability and ideal target dosing range for quetiapine treatment of cannabis dependence over an eight-week period. The purpose of this pilot study is to obtain preliminary data regarding the potential efficacy, tolerability and safety of quetiapine treatment of cannabis dependence before conducting a larger double-blind trial.

Official TitleOpen-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence
NCT00954681
Principal SponsorNew York State Psychiatric Institute
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

15 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersMarijuana AbuseSubstance-Related DisordersChemically-Induced Disorders

Criteria

5 inclusion criteria required to participate
Between the ages of 18-65
Meets DSM-IV criteria for current cannabis dependence
Seeking treatment for cannabis dependence
Reports using cannabis an average of five days per week over the past 28 days
Show More Criteria
10 exclusion criteria prevent from participating
Lifetime history of DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
Current DSM-IV criteria for any other psychiatric disorder that may, according to the investigator's judgment, require either pharmacological or non-pharmacological intervention over the course of the study
Receiving prescribed psychotropic medication
Known history of allergy, intolerance, or hypersensitivity to quetiapine
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Open label treatment with quetiapine

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Substance Treatment Research Service (STARS) of Columbia University

New York, United StatesOpen Substance Treatment Research Service (STARS) of Columbia University in Google Maps
CompletedOne Study Center